Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MLLT6 maintains PD‐L1 expression and mediates tumor immune resistance

15 Oct 2020

Abstract excerpt

Tumor cells subvert immune surveillance by harnessing signals from immune checkpoints to acquire immune resistance. The protein PD‐L1 is an important component in this process, and inhibition of PD‐L1 elicits durable anti‐tumor responses in a broad spectrum of cancers. However, immune checkpoint inhibition that target known pathways is not universally effective. A better understanding of the genetic repertoire...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33063451
DOI: 10.15252/embr.202050155

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MLLT6 maintains PD‐L1 expression and mediates tumor immune resistancePMID 33063451Read ↗

PRMT1 acts as a suppressor of MHC-I and anti-tumor immunitySemantic proximity Read ↗

Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer CellsSemantic proximity Read ↗

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated CytotoxicitySemantic proximity Read ↗

CRISPR Activation Screening Identifies VGLL3–TEAD1–RUNX1/3 as a Transcriptional Complex for PD-L1 ExpressionSemantic proximity Read ↗

Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulatorsSemantic proximity Read ↗

Pan-cancer mapping of single T cell profiles reveals a TCF1:CXCR6-CXCL16 regulatory axis essential for effective anti-tumor immunitySemantic proximity Read ↗

The Cul5 E3 Ligase Complex Is a Key Negative Feedback Regulator of TCR/IL2 Signaling and Anti-Tumor Activity in CD8 <sup>+</sup> T CellsSemantic proximity Read ↗

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.Semantic proximity Read ↗

Tumor immune checkpoints and their associated inhibitorsSemantic proximity Read ↗

CRISPR screens establish regulatory maps of immunosuppressive surface molecules in cancerSemantic proximity Read ↗

Suppression of tumor/host intrinsic CMTM6 drives anti-tumor cytotoxicity in a PD-L1 independent mannerSemantic proximity Read ↗

Myeloid-specific KDM6B inhibition sensitizes Glioblastoma to PD1 blockadeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.